“And as an illustration to this, I may share with the committee that even last evening we were looking at two case reports of allergic reactions. We know from the very extensive clinical trials that this wasn’t a feature. But if we need to strengthen our advice…. we get that advice to the field immediately.”
Tag: Pfizer
WHO looks at giving Covid-19 to healthy people to speed up vaccine trials
RFK, Jr. Urges FDA to Slow Down COVID Vaccine Approval Process
RFK, Jr. Urges FDA to Slow Down COVID Vaccine Approval Process
In a letter to Peter Marks, director of the Center for Biologics Evaluation and Research, Robert F. Kennedy, Jr. asks the U.S. Food and Drug Administration to take a cautious approach in approving COVID-19 vaccines that have been developed at “warp speed.”
People who get injured from COVID-19 vaccines could have a hard time getting compensated
People who get injured from COVID-19 vaccines could have a hard time getting compensated
Not only does CICP deny compensation for pain and suffering and attorney’s fees, and the right to appeals, it prohibits litigants from holding hearings and introducing evidence and expert testimony. Another CICP disadvantage, Pop said, is that the only the government’s own expert can form the basis for what constitutes a permissible claim. Therefore, he said, under the CICP program, it seems highly unlikely that any individual with a reaction that’s not “open and notorious, even though rare,” could ever get any kind of compensation.
MIT machine learning models find gaps in coverage by Moderna, Pfizer, other Warp Speed COVID-19 vaccines
Vaccines to block COVID-19 that are in development by Moderna, Pfizer, AstraZeneca and others, and that are currently in Phase III clinical trials, may not do as well covering people of Black or Asian genetic ancestry as they do for white people, a study released Wednesday by the Massachusetts Institute of Technology indicated.
Long-Term-Care Residents and Health Workers Should Get Vaccine First, C.D.C. Panel Says
Long-Term-Care Residents and Health Workers Should Get Vaccine First, C.D.C. Panel Says
The only member of the committee to vote against the recommendation was Dr. Helen Talbot, an infectious-disease specialist at Vanderbilt University, who expressed discomfort with putting long-term-care residents in the first priority group because the vaccines’ safety had not been studied in that particular population. “We enter this realm of ‘we hope it works and we hope it’s safe,’ and that concerns me on many levels,” she said before the vote.
Highly recommended YouTube video:
Great Reset is Not Communism it is Neofeudalism via Resource and Individual Extractivism
EU criticises ‘hasty’ UK approval of COVID-19 vaccine
EU criticises ‘hasty’ UK approval of COVID-19 vaccine
European Medicines Agency says its approval process is more appropriate, as German politician calls UK move ‘problematic’.
Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says
Emergency approval of coronavirus vaccines is not guaranteed, FDA commissioner says
Career scientists at the FDA are reviewing raw data from the Pfizer and Moderna trials for the first time, investigating any adverse events or side effects that transpired over the course of the trials, different levels of effectiveness among populations and age groups, and whether individuals who were already infected by the coronavirus might have had any unexpected reactions to the vaccine doses.
Hahn said they will also be looking for evidence that the vaccines lead to increased respiratory infections – a concern with vaccines produced for other coronaviruses, such as SARS and MERS – and whether the use of a relatively new method of vaccine development, known as messenger RNA technology, poses any significant risks.
Keep the mask: A vaccine won’t end the U.S. crisis right away — It could be well into 2021 before things get close to normal
Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic
Successful Not-for-Profit Oxford COVID Vaccine Threatens Big Pharma Profit Logic
“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker
You must be logged in to post a comment.